1. Academic Validation
  2. Luteolin Ameliorates Experimental Pulmonary Arterial Hypertension via Suppressing Hippo-YAP/PI3K/AKT Signaling Pathway

Luteolin Ameliorates Experimental Pulmonary Arterial Hypertension via Suppressing Hippo-YAP/PI3K/AKT Signaling Pathway

  • Front Pharmacol. 2021 Apr 15;12:663551. doi: 10.3389/fphar.2021.663551.
Wanyun Zuo 1 Na Liu 1 Yunhong Zeng 2 Zhenghui Xiao 2 Keke Wu 1 Fan Yang 1 Biao Li 1 Qingqing Song 1 Yunbin Xiao 2 Qiming Liu 1
Affiliations

Affiliations

  • 1 Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, Hunan, China.
  • 2 Department of Cardiology, Hunan Children's Hospital, Hunan, China.
Abstract

Luteolin is a flavonoid compound with a variety of pharmacological effects. In this study, we explored the effects of luteolin on monocrotaline (MCT) induced rat pulmonary arterial hypertension (PAH) and underlying mechanisms. A rat PAH model was generated through MCT injection. In this model, luteolin improved pulmonary vascular remodeling and right ventricular hypertrophy, meanwhile, luteolin could inhibit the proliferation and migration of pulmonary artery smooth muscle cells induced by platelet-derived growth factor-BB (PDGF-BB) in a dose-dependent manner. Moreover, our results showed that luteolin could downregulate the expression of LATS1 and YAP, decrease YAP nuclear localization, reduce the expression of PI3K, and thereby restrain the phosphorylation of Akt induced by PDGF-BB. In conclusion, luteolin ameliorated experimental PAH, which was at least partly mediated through suppressing HIPPO-YAP/PI3K/Akt signaling pathway. Therefore, luteolin might become a promising candidate for treatment of PAH.

Keywords

PI3K; Pulmonary arterial hypertension; akt; hippo-yap; luteolin.

Figures
Products